NVP-ABE171

NVP-ABE171 is an efficient, long-lasting and orally active PDE4 inhibitor with IC50 values for PDE4D, PDE4B, PDE4A and PDE4C of 1.5, 34, 602 and 1230 nM respectively. NVP-ABE171 enhances the cAMP accumulation induced by isoproterenol, inhibits the oxidative burst of eosinophils and the release of inflammatory cytokines from T cells and monocytes. NVP-ABE171 exhibits potent anti-inflammatory activity in animal models of asthma and pulmonary inflammation. NVP-ABE171 can be used for research on asthma and chronic obstructive pulmonary disease[1].

Product Specifications

CAS Number

[426268-06-6]

UNSPSC

12352005

Target

Phosphodiesterase (PDE)

Related Pathways

Metabolic Enzyme/Protease

Field of Research

Inflammation/Immunology

Smiles

O=C(O)C1=CC=C(C2=NC(C3=CC4=NON=C4C=C3)=C5N=CC=CC5=C2)C=C1

Molecular Formula

C21H12N4O3

Molecular Weight

368.34

References & Citations

[1]Trifilieff A, et al. Pharmacological profile of a novel phosphodiesterase 4 inhibitor, 4- (8-benzo[1,2,5]oxadiazol-5-yl-[1,7]naphthyridin-6-yl) -benzoic acid (NVP-ABE171), a 1,7-naphthyridine derivative, with anti-inflammatory activities. J Pharmacol Exp Ther. 2002 Apr;301 (1) :241-8.